Akero Therapeutics, Inc. (NASDAQ:AKRO) VP Patrick Lamy Sells 1,000 Shares

Akero Therapeutics, Inc. (NASDAQ:AKRO) VP Patrick Lamy sold 1,000 shares of the company’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $48.09, for a total transaction of $48,090.00. Following the sale, the vice president now owns 33,492 shares in the company, valued at $1,610,630.28. The trade was a 2.90 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

Patrick Lamy also recently made the following trade(s):

• On Monday, January 27th, Patrick Lamy sold 5,000 shares of Akero Therapeutics stock. The stock was sold at an average price of $57.03, for a total transaction of $285,150.00.
• On Monday, December 16th, Patrick Lamy sold 1,000 shares of Akero Therapeutics stock. The stock was sold at an average price of $29.13, for a total transaction of $29,130.00.
• On Tuesday, December 10th, Patrick Lamy sold 925 shares of Akero Therapeutics stock. The shares were sold at an average price of $30.79, for a total transaction of $28,480.75.

Akero Therapeutics Price Performance

Shares of NASDAQ AKRO opened at $45.13 on Thursday. The company has a debt-to-equity ratio of 0.05, a current ratio of 17.25 and a quick ratio of 17.25. The stock has a fifty day moving average price of $39.92 and a 200 day moving average price of $33.00. Akero Therapeutics, Inc. has a 1-year low of $17.86 and a 1-year high of $58.40. The company has a market cap of $3.15 billion, a PE ratio of -12.03 and a beta of -0.19.

Akero Therapeutics (NASDAQ:AKRO) last issued its quarterly earnings results on Friday, February 28th. The company reported ($0.99) earnings per share for the quarter, missing the consensus estimate of ($0.98) by ($0.01). Sell-side analysts forecast that Akero Therapeutics, Inc. will post -3.99 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. GF Fund Management CO. LTD. purchased a new position in Akero Therapeutics in the fourth quarter worth $41,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in Akero Therapeutics by 18.3% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 71,451 shares of the company’s stock worth $1,988,000 after acquiring an additional 11,035 shares in the last quarter. Woodline Partners LP increased its position in shares of Akero Therapeutics by 29.9% in the fourth quarter. Woodline Partners LP now owns 379,967 shares of the company’s stock valued at $10,571,000 after buying an additional 87,499 shares in the last quarter. Two Sigma Advisers LP increased its position in shares of Akero Therapeutics by 195.7% in the fourth quarter. Two Sigma Advisers LP now owns 41,100 shares of the company’s stock valued at $1,143,000 after buying an additional 27,200 shares in the last quarter. Finally, Two Sigma Investments LP increased its position in shares of Akero Therapeutics by 43.3% in the fourth quarter. Two Sigma Investments LP now owns 127,320 shares of the company’s stock valued at $3,542,000 after buying an additional 38,500 shares in the last quarter.

Wall Street Analysts Forecast Growth

AKRO has been the topic of several recent analyst reports. Morgan Stanley increased their price target on shares of Akero Therapeutics from $46.00 to $96.00 and gave the company an “overweight” rating in a research note on Tuesday, January 28th. Canaccord Genuity Group increased their price target on shares of Akero Therapeutics from $56.00 to $73.00 and gave the company a “buy” rating in a research note on Tuesday, January 28th. HC Wainwright increased their price target on shares of Akero Therapeutics from $72.00 to $75.00 and gave the company a “buy” rating in a research note on Monday. Citigroup increased their price target on shares of Akero Therapeutics from $65.00 to $80.00 and gave the company a “buy” rating in a research note on Tuesday, January 28th. Finally, Bank of America raised Akero Therapeutics from a “neutral” rating to a “buy” rating and increased their price objective for the company from $35.00 to $63.00 in a report on Thursday, January 30th. Nine equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $76.29.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.